Silo Pharma, Inc. (Nasdaq: SILO) ('Silo” or 'the Company), a diversified developmental-stage biopharmaceutical and ...

BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, ...

FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS HOUSTON, Aug. 25, 2025 ...

As 2026 approaches, now is the time to reflect on the victories from the year and the lessons to be taken moving forward.

The “plausible mechanism pathway” will allow personalised drugs to reach the market sooner for patients with genetic diseases ...

As Congress and the courts reaffirm federal supremacy in cannabis-hemp regulation, MMJ International Holdings stands with a DEA licensed lab, two accepted FDA Investigational new drug applications, ...

BURLINGAME, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company engaged in the discovery and development of innovative multi-specific medicines, announced ...

Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic ...

“Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers,” by Dewpoint Therapeutics. News release; Oct. 21, 2025. For more news on cancer ...

The MarketWatch News Department was not involved in the creation of this content. BURLINGAME, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company engaged ...